Skip to main content
SpringerLink
Log in

Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

An Australian state database was used to test the validity of the Quantitative tumor/node/metastasis (QTNM) staging system for assessing prognosis of differentiated thyroid cancer (DTC) on the basis of four variables quantified at diagnosis (histopathology, age, node involvement, and tumor size). Using the Queensland Cancer Registry (QCR), we identified 788 cases of DTC diagnosed from 1982 to 2006 with complete staging information. Causes of death were ascertained by linking the QCR database with the Australian National Death Index. Subjects were staged according to AJCC TNM 7th edition and QTNM, and cancer-specific survival (CSS) was calculated by the Kaplan–Meier method. Cancer-specific mortality was observed in 22 (2.8 %) patients, with 10-year CSS for the cohort of 97.0 % at a median follow-up of 262.8 months. QTNM stage specific cancer survival at 10 years was 99.6, 97.0, and 78.6 % for low-, intermediate-, and high-risk groups, respectively. This was comparable to the original US dataset in which the QTNM was initially studied, and it fared better at discriminating survival than the standard TNM system, where there was overlap in survival between stages. The current study validates the QTNM system in an Australian cohort and shows at least equivalent discriminatory capacity to the current TNM staging system. The QTNM utilized prognostic variables of significance to produce an optimal three-stage stratification scheme. Given, its advantage in clearly discriminating between prognostic groups, clinical relevance and simplicity of use, we recommend that TNM be replaced with QTNM for risk stratification for both recurrence and CSS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. F. Bray, J.S. Ren, E. Masuyer, J. Ferlay, Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int. J. Cancer (2012). doi:10.1002/ijc.27711

    Google Scholar 

  2. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, D. M. Parkin, GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. (2010), http://globocan.iarc.fr

  3. Australian Institute of Health and Welfare (AIHW), ACIM (Australian Cancer Incidence and Mortality) Books (AIHW, Canberra, 2012)

    Google Scholar 

  4. S.A. Hundahl, I.D. Fleming, A.M. Fremgen, H.R. Menck, A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995. Cancer 83(12), 2638–2648 (1998). doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1

    Google Scholar 

  5. D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167–1214 (2009). doi:10.1089/thy.2009.0110

    Article  PubMed  Google Scholar 

  6. H.B. Burke, D.E. Henson, Criteria for prognostic factors and for an enhanced prognostic system. Cancer 72(10), 3131–3135 (1993). doi:10.1002/1097-0142(19931115)72:10<3131::aid-cncr2820721039>3.0.co;2-j

  7. H.B. Burke, Outcome prediction and the future of the TNM staging system. J. Natl. Cancer Inst. 96(19), 1408–1409 (2004). doi:10.1093/jnci/djh293

    Article  PubMed  Google Scholar 

  8. P. Hermanek, L.H. Sobin, C. Wittekind, How to improve the present TNM staging system. Cancer 86(11), 2189–2191 (1999). doi:10.1002/(sici)1097-0142(19991201)86:11<2189::aid-cncr1>3.0.co;2-r

    Google Scholar 

  9. J.R. Egner, AJCC Cancer Staging Manual, 7th edn. (Springer, New York, 2010)

    Google Scholar 

  10. A.A. Onitilo, J.M. Engel, C.I. Lundgren, P. Hall, L. Thalib, S.A.R. Doi, Simplifying the TNM system for clinical use in differentiated thyroid cancer. J. Clin. Oncol. 27(11), 1872–1878 (2009). doi:10.1200/jco.2008.20.2382

    Article  PubMed  Google Scholar 

  11. H.S. Tran Cao, L.E. Johnston, D.C. Chang, M. Bouvet, A critical analysis of the American Joint Committee on Cancer (AJCC) staging system for differentiated thyroid carcinoma in young patients on the basis of the surveillance, epidemiology, and end results (SEER) registry. Surgery 152(2), 145–151 (2012). doi:10.1016/j.surg.2012.02.015

    Article  PubMed  Google Scholar 

  12. S.I. Sherman, J.D. Brierley, M. Sperling, K.B. Ain, S.T. Bigos, D.S. Cooper, B.R. Haugen, M. Ho, I. Klein, P.W. Ladenson, J. Robbins, D.S. Ross, B. Specker, T. Taylor, H.R. Maxon, Prospective multicenter study of thyroid carcinoma treatment. Cancer 83(5), 1012–1021 (1998). doi:10.1002/(sici)1097-0142(19980901)83:5<1012::aid-cncr28>3.0.co;2-9

    Google Scholar 

  13. Y. Ito, A. Miyauchi, T. Jikuzono, T. Higashiyama, Y. Takamura, A. Miya, K. Kobayashi, F. Matsuzuka, K. Ichihara, K. Kuma, Risk factors contributing to a poor prognosis of papillary thyroid carcinoma: validity of UICC/AJCC TNM classification and stage grouping. World J. Surg. 31(4), 838–848 (2007). doi:10.1007/s00268-006-0455-0

    Article  PubMed  Google Scholar 

  14. A. Jukkola, R. Bloigu, T. Ebeling, P. Salmela, G. Blanco, Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr. Relat. Cancer 11(3), 571–579 (2004). doi:10.1677/erc.1.00826

    Article  PubMed  Google Scholar 

  15. S. Beenken, D. Roye, H. Weiss, M. Sellers, M. Urist, A. Diethelm, H. Goepfert, Extent of surgery for intermediate-risk well-differentiated thyroid cancer. Am. J. Surg. 179(1), 51–56 (2000). doi:10.1016/s0002-9610(99)00254-8

    Article  CAS  PubMed  Google Scholar 

  16. C. Kahn, L. Simonella, M. Sywak, S. Boyages, O. Ung, D. O’Connell, Postsurgical pathology reporting of thyroid cancer in New South Wales, Australia. Thyroid 22(6), 604–610 (2012). doi:10.1089/thy.2011.0501

    Article  PubMed  Google Scholar 

  17. F.E. Harrell Jr, K.L. Lee, D.B. Mark, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15(4), 361–387 (1996). doi:10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4

  18. P. Royston, W. Sauerbrei, A new measure of prognostic separation in survival data. Stat. Med. 23(5), 723–748 (2004). doi:10.1002/sim.1621

    Article  PubMed  Google Scholar 

  19. J.D. Brierley, T. Panzarella, R.W. Tsang, M.K. Gospodarowicz, B. O’Sullivan, A comparison of different staging systems predictability of patient outcome. Cancer 79(12), 2414–2423 (1997). doi:10.1002/(sici)1097-0142(19970615)79:12<2414::aid-cncr18>3.0.co;2-u

    Google Scholar 

  20. K.-C. Loh, F.S. Greenspan, L. Gee, T.R. Miller, P.P.B. Yeo, Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J. Clin. Endocrinol. Metab. 82(11), 3553–3562 (1997). doi:10.1210/jc.82.11.3553

    Article  CAS  PubMed  Google Scholar 

  21. B.H.-H. Lang, C.-Y. Lo, W.-F. Chan, K.-Y. Lam, K.-Y. Wan, Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: stage migration and predictability. Ann. Surg. Oncol. 14(5), 1551–1559 (2007). doi:10.1245/s10434-006-9242-2

    Article  PubMed  Google Scholar 

  22. B.H.-H. Lang, C.-Y. Lo, W.-F. Chan, K.-Y. Lam, K.-Y. Wan, Staging systems for papillary thyroid carcinoma: a review and comparison. Ann. Surg. 245(3), 366–378 (2007). doi:10.1097/01.sla.0000250445.92336.2a

    Article  PubMed Central  PubMed  Google Scholar 

  23. F.A. Verburg, U. Mader, C.L. Kruitwagen, M. Luster, C. Reiners, A comparison of prognostic classification systems for differentiated thyroid carcinoma. Clin. Endocrinol. 72(6), 830–838 (2010). doi:10.1111/j.1365-2265.2009.03734.x

    Article  Google Scholar 

  24. C.-Y. Lo, W.-F. Chan, K.-Y. Lam, K.-Y. Wan, Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival. Ann. Surg. 242(5), 708–715 (2005)

    Article  PubMed Central  PubMed  Google Scholar 

  25. B.H.-H. Lang, C.-Y. Lo, W.-F. Chan, K.-Y. Lam, K.-Y. Wan, Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre. Endocr. Relat. Cancer 14(1), 29–42 (2007). doi:10.1677/erc.1.01284

    Article  PubMed  Google Scholar 

  26. C. Passler, G. Prager, C. Scheuba, K. Kaserer, G. Zettinig, B. Niederle, Application of staging systems for differentiated thyroid carcinoma in an endemic goiter region with iodine substitution. Ann. Surg. 237(2), 227–234 (2003). doi:10.1097/01.sla.0000048449.69472.81

    PubMed Central  PubMed  Google Scholar 

  27. I.D. Hay, E.J. Bergstralh, J.R. Goellner, J.R. Ebersold, C.S. Grant, Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through. Surgery 114(6), 1050–1057 (1989). discussion 1057–1058

    Google Scholar 

  28. A. D’Avanzo, P. Ituarte, P. Treseler, E. Kebebew, J. Wu, M. Wong, Q.Y. Duh, A.E. Siperstein, O.H. Clark, Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Thyroid 14(6), 453–458 (2004). doi:10.1089/105072504323150778

    Article  PubMed  Google Scholar 

  29. B.H.-H. Lang, S.M. Chow, C.Y. Lo, S.C. Law, K.Y. Lam, Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers. Ann. Surg. 246(1), 114–121 (2007). doi:10.1097/01.sla.0000262785.46403.9b

    Article  PubMed Central  PubMed  Google Scholar 

  30. A.R. Shaha, TNM classification of thyroid carcinoma. World J. Surg. 31(5), 879–887 (2007). doi:10.1007/s00268-006-0864-0

    Article  PubMed  Google Scholar 

  31. N. Wada, H. Nakayama, N. Suganuma, Y. Masudo, Y. Rino, M. Masuda, T. Imada, Prognostic value of the sixth edition AJCC/UICC TNM classification for differentiated thyroid carcinoma with extrathyroid extension. J. Clin. Endocrinol. Metab. 92(1), 215–218 (2007). doi:10.1210/jc.2006-1443

    Article  CAS  PubMed  Google Scholar 

  32. A. Guerra, L. Fugazzola, V. Marotta, M. Cirillo, S. Rossi, V. Cirello, I. Forno, T. Moccia, A. Budillon, M. Vitale, A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J. Clin. Endocrinol. Metab. 97(7), 2333–2340 (2012). doi:10.1210/jc.2011-3106

    Article  CAS  PubMed  Google Scholar 

  33. V. Marotta, M.R. Sapio, A. Guerra, M. Vitale, BRAF mutation in cytology samples as a diagnostic tool for papillary thyroid carcinoma. Expert. Opin. Med. Diagn. 5(4), 277–290 (2011). doi:10.1517/17530059.2011.575058

    Article  CAS  PubMed  Google Scholar 

  34. I.D. Hay, C.S. Grant, W.F. Taylor, W.M. McConahey, Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102(6), 1088–1095 (1987)

    CAS  PubMed  Google Scholar 

  35. L.A. Akslen, V.A. LiVolsi, Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer 88(8), 1902–1908 (2000). doi:10.1002/(sici)1097-0142(20000415)88:8<1902::aid-cncr20>3.0.co;2-y

    Google Scholar 

  36. J.L. Pasieka, J. Zedenius, G. Auer, L. Grimelius, A. Hoog, G. Lundell, G. Wallin, M. Backdahl, Addition of nuclear DNA content to the AMES risk-group classification for papillary thyroid cancer. Surgery 112(6), 1154–1159 (1992). discussion 1159-1160

    CAS  PubMed  Google Scholar 

  37. L.A. Akslen, Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer 72(9), 2680–2685 (1993). doi:10.1002/1097-0142(19931101)72:9<2680::aid-cncr2820720926>3.0.co;2-d

    Google Scholar 

  38. S. Noguchi, N. Murakami, H. Kawamoto, Classification of papillary cancer of the thyroid based on prognosis. World J. Surg. 18(4), 552–557 (1994). doi:10.1007/bf00353763

    Article  CAS  PubMed  Google Scholar 

  39. A. Konturek, M. Barczynski, W. Nowak, P. Richter, Prognostic factors in differentiated thyroid cancer–a 20-year surgical outcome study. Langenbecks Arch. Surg. 397(5), 809–815 (2012). doi:10.1007/s00423-011-0899-z

    Article  PubMed Central  PubMed  Google Scholar 

  40. S. Sebastian, J. Gonzalez, P. Paricio, J. Perez, D. Flores, A. Madrona, P. Romero, F. Tebar, Papillary thyroid carcinoma: prognostic index for survival including the histological variety. Arch. Surg. 135(3), 272–277 (2000). doi:10.1001/archsurg.135.3.272

    Article  CAS  PubMed  Google Scholar 

  41. I. Sugitani, N. Kasai, Y. Fujimoto, A. Yanagisawa, A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 135(2), 139–148 (2004). doi:10.1016/s0039-6060(03)00384-2

    Article  PubMed  Google Scholar 

  42. E. Yildirim, A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems. J. Am. Coll. Surg. 200(3), 378–392 (2005). doi:10.1016/j.jamcollsurg.2004.10.031

    Article  PubMed  Google Scholar 

  43. R. Wong, C. Bresee, G. Braunstein, Comparison with published systems of a new staging system for papillary and follicular thyroid carcinomas. Thyroid (2012). doi:10.1089/thy.2012.0181

    Google Scholar 

  44. L.J. DeGroot, E.L. Kaplan, M. McCormick, F.H. Straus, Natural history, treatment, and course of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 71(2), 414–424 (1990)

    Article  CAS  PubMed  Google Scholar 

  45. E.L. Mazzaferri, S.M. Jhiang, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97(5), 418–428 (1994). doi:10.1016/0002-9343(94)90321-2

    Article  CAS  PubMed  Google Scholar 

  46. A.R. Shaha, T.R. Loree, J.P. Shah, Intermediate-risk group for differentiated carcinoma of thyroid. Surgery 116(6), 1036–1040 (1994). discussion 1040-1031

    CAS  PubMed  Google Scholar 

  47. B. Cady, R. Rossi, An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104(6), 947–953 (1988)

    CAS  PubMed  Google Scholar 

  48. D.P. Byar, S.B. Green, P. Dor, E.D. Williams, J. Colon, H.A. van Gilse, M. Mayer, R.J. Sylvester, M. Van Glabbeke, A prognostic index for thyroid carcinoma. A study of the EORTC thyroid cancer cooperative group. Eur. J. Cancer 15(8), 1033–1041 (1979). doi:10.1016/0014-2964(79)90291-3

    Article  CAS  PubMed  Google Scholar 

  49. H. Lerch, O. Schober, T. Kuwert, H.B. Saur, Survival of differentiated thyroid carcinoma studied in 500 patients. J. Clin. Oncol. 15(5), 2067–2075 (1997)

    CAS  PubMed  Google Scholar 

  50. Y. Ito, K. Ichihara, H. Masuoka, M. Fukushima, H. Inoue, M. Kihara, C. Tomoda, T. Higashiyama, Y. Takamura, K. Kobayashi, A. Miya, A. Miyauchi, Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma. World J. Surg. 34(11), 2570–2580 (2010). doi:10.1007/s00268-010-0710-2

    Article  PubMed  Google Scholar 

  51. M. Sellers, S. Beenken, A. Blankenship, S-j Soong, E. Turbat-Herrera, M. Urist, W. Maddox, Prognostic significance of cervical lymph node metastases in differentiated thyroid cancer. Am. J. Surg. 164(6), 578–581 (1992). doi:10.1016/s0002-9610(05)80710-x

    Article  CAS  PubMed  Google Scholar 

  52. S.G. de Meer, M. Dauwan, B. de Keizer, G.D. Valk, I.H. Borel Rinkes, M.R. Vriens, Not the number but the location of lymph nodes matters for recurrence rate and disease-free survival in patients with differentiated thyroid cancer. World J. Surg. 36(6), 1262–1267 (2012)

    Article  PubMed Central  PubMed  Google Scholar 

  53. N. Sato, M. Oyamatsu, Y. Koyama, I. Emura, Y. Tamiya, K. Hatakeyama, Do the level of nodal disease according to the TNM classification and the number of involved cervical nodes reflect prognosis in patients with differentiated carcinoma of the thyroid gland? J. Surg. Oncol. 69(3), 151–155 (1998). doi:10.1002/(sici)1096-9098(199811)69:3<151::aid-jso6>3.0.co;2-v

  54. N.J. Beasley, J. Lee, S. Eski, P. Walfish, I. Witterick, J.L. Freeman, Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer. Arch. Otolaryngol. Head. Neck. Surg. 128(7), 825–828 (2002). doi:10.1001/archotol.128.7.825

    Article  PubMed  Google Scholar 

  55. C.I. Lundgren, P. Hall, P.W. Dickman, J. Zedenius, Clinically significant prognostic factors for differentiated thyroid carcinoma. Cancer 106(3), 524–531 (2006). doi:10.1002/cncr.21653

    Article  PubMed  Google Scholar 

  56. A. Shaha, Treatment of thyroid cancer based on risk groups. J. Surg. Oncol. 94(8), 683–691 (2006). doi:10.1002/jso.20697

    Article  PubMed  Google Scholar 

  57. M.R. Pelizzo, I.M. Boschin, A. Toniato, A. Piotto, C. Pagetta, M.D. Gross, A. Al-Nahhas, D. Rubello, Papillary thyroid carcinoma: 35-year outcome and prognostic factors in 1858 patients. Clin. Nucl. Med. 32(6), 440–444 (2007). doi:10.1097/RLU.0b013e31805375ca

    Article  PubMed  Google Scholar 

  58. M. Haq, C. Harmer, Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin. Endocrinol. 63(1), 87–93 (2005). doi:10.1111/j.1365-2265.2005.02304.x

    Article  CAS  Google Scholar 

  59. J.R. Clark, P. Lai, F. Hall, A. Borglund, S. Eski, J.L. Freeman, Variables predicting distant metastases in thyroid cancer. Laryngoscope 115(4), 661–667 (2005)

    Article  PubMed  Google Scholar 

  60. B.H.-H. Lang, C.-Y. Lo, Cancer: QTNM: a simplified TNM or just another staging system? Nat. Rev. Endocrinol. 5(10), 531–532 (2009)

    Article  PubMed  Google Scholar 

  61. B. Cady, Staging in thyroid carcinoma. Cancer 83(5), 844–847 (1998)

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. School of Medicine, University of Queensland, Brisbane, Australia

    Daniel Mankarios, Robin H. Mortimer & Anthony Russell

  2. Cancer Council Queensland, Brisbane, QLD, Australia

    Peter Baade & Pip Youl

  3. Royal Brisbane Hospital, Brisbane, QLD, Australia

    Robin H. Mortimer

  4. Department of Hematology/Oncology, Marshfield Clinic Weston Center, 3501 Cranberry Boulevard, Weston, WI, 54476, USA

    Adedayo A. Onitilo

  5. Department of Endocrinology, Princess Alexandra Hospital, Brisbane, QLD, Australia

    Anthony Russell & Suhail A. R. Doi

  6. Clinical Epidemiology Unit, School of Population Health, University of Queensland, Brisbane, QLD, Australia

    Adedayo A. Onitilo & Suhail A. R. Doi

Authors
  1. Daniel Mankarios
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Baade
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pip Youl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robin H. Mortimer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Adedayo A. Onitilo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anthony Russell
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Suhail A. R. Doi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suhail A. R. Doi.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 34 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mankarios, D., Baade, P., Youl, P. et al. Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer. Endocrine 46, 300–308 (2014). https://doi.org/10.1007/s12020-013-0078-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-013-0078-9

Keywords

Search

Navigation